IP Library Granted Patent US 8,734,770
Granted Patent B2
US 8,734,770 · App. 13/585,692 · Granted May 27, 2014

Methods and compositions for administration of TRPV1 agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,734,770
App. No.
13/585,692
Granted
May 27, 2014
Kind
B2
Abstract

Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.

Claims (29)

1. A liquid formulation comprising:

about 20% (w/v) capsaicin;

a solvent system, the solvent system comprising about 60% (v/v) to about 90% (v/v) propylene glycol and about 10% (v/v) to about 30% (v/v) oleyl alcohol; and

less than 1% (w/v) of a stabilizer.

2. The liquid formulation of claim 1 , further comprising a local anesthetic.

3. The liquid formulation of claim 1 , wherein the liquid formulation is contained in a microemulsion.

4. The liquid formulation of claim 1 , wherein the stabilizer is selected from the group consisting of antioxidants, chelators, preservatives, disodium edetate, beta-carotene, tocopherols, beta-tocopherols, tocopherol acetate, octyl gallate, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, antimicrobial agents, parabens, methylparaben, propylparaben, butylparaben, methyl salicylate, phenethyl alcohol, and resorcinol.

5. The liquid formulation of claim 4 , wherein the stabilizer is butylated hydroxytoluene.

6. The liquid formulation of claim 1 , wherein the solvent system comprises about 60% (v/v) propylene glycol.

7. The liquid formulation of claim 1 , wherein the solvent system comprises about 70% (v/v) propylene glycol.

8. The liquid formulation of claim 1 , wherein the solvent system comprises about 75% (v/v) propylene glycol.

9. The liquid formulation of claim 1 , wherein the solvent system comprises about 80% (v/v) propylene glycol.

10. The liquid formulation of claim 1 , wherein the solvent system comprises about 90% (v/v) propylene glycol.

11. The liquid formulation of claim 1 , wherein the solvent system comprises about 10% (v/v) oleyl alcohol.

12. The liquid formulation of claim 1 , wherein the solvent system comprises about 25% (v/v) oleyl alcohol.

13. The liquid formulation of claim 1 , wherein the solvent system comprises about 30% (v/v) oleyl alcohol.

14. The liquid formulation of claim 1 , further comprising less than 1% of a colorant.

15. The liquid formulation of claim 6 , wherein the stabilizer is butylated hydroxytoluene.

16. The liquid formulation of claim 7 , wherein the stabilizer is butylated hydroxytoluene.

17. A liquid formulation comprising:

about 20% (w/v) capsaicin;

a solvent system, the solvent system comprising about 70% (v/v) propylene glycol and the remainder oleyl alcohol; and

less than about 1% (w/v) of a stabilizer.

18. The liquid formulation of claim 17 , wherein the stabilizer is butylated hydroxytoluene.

19. A liquid formulation comprising:

about 20% (w/v) capsaicin;

a solvent system, the solvent system comprising about 60% (v/v) propylene glycol and the remainder oleyl alcohol; and

less than about 1% (w/v) of a stabilizer.

20. The liquid formulation of claim 19 , wherein the stabilizer is butylated hydroxytoluene.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2019
From: GRÜNENTHAL GMBH
To: GRT US HOLDING, INC.
Reel/Frame 050065/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2019
From: ACORDA THERAPEUTICS, INC.
To: GRÜNENTHAL GMBH
Reel/Frame 049260/0707 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2013
From: NEUROGESX, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 031751/0333 →
ASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Jul 10, 2013
From: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
To: NEUROGESX, INC.
Reel/Frame 030777/0782 →
SECURITY AGREEMENT Recorded Nov 13, 2012
From: NEUROGESX, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 029291/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2012
From: MUHAMMAD, NAWEED; JAMIESON, GENE C.; BLEY, KEITH R.; CHANDA, SANJAY
To: NEUROGESX, INC.
Reel/Frame 028793/0266 →